Your browser doesn't support javascript.
loading
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
Jabbour, Elias J; Sasaki, Koji; Ravandi, Farhad; Short, Nicholas J; Garcia-Manero, Guillermo; Daver, Naval; Kadia, Tapan; Konopleva, Marina; Jain, Nitin; Cortes, Jorge; Issa, Ghayas C; Jacob, Jovitta; Kwari, Monica; Thompson, Philip; Garris, Rebecca; Pemmaraju, Naveen; Yilmaz, Musa; O'Brien, Susan M; Kantarjian, Hagop M.
Afiliação
  • Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cortes J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jacob J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kwari M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Thompson P; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Garris R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • O'Brien SM; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California.
  • Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer ; 125(15): 2579-2586, 2019 08 01.
Article em En | MEDLINE | ID: mdl-30985931
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Leucemia-Linfoma Linfoblástico de Células Precursoras / Antineoplásicos Imunológicos / Inotuzumab Ozogamicina Tipo de estudo: Prognostic_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Leucemia-Linfoma Linfoblástico de Células Precursoras / Antineoplásicos Imunológicos / Inotuzumab Ozogamicina Tipo de estudo: Prognostic_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article